Biopharmx Corp (NYSE: BPMX) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap bio therapeutic drugs companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Biopharmx Corp and Proteon Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biopharmx Corp 0 0 1 0 3.00
Proteon Therapeutics 0 7 1 0 2.13

Biopharmx Corp presently has a consensus price target of $3.00, suggesting a potential upside of 1,614.29%. Proteon Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 250.00%. Given Biopharmx Corp’s stronger consensus rating and higher probable upside, equities analysts clearly believe Biopharmx Corp is more favorable than Proteon Therapeutics.

Valuation and Earnings

This table compares Biopharmx Corp and Proteon Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Biopharmx Corp N/A N/A N/A ($0.34) -0.51
Proteon Therapeutics $2.95 million 11.95 -$28.52 million ($1.57) -1.27

Biopharmx Corp has higher revenue, but lower earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Biopharmx Corp, indicating that it is currently the more affordable of the two stocks.


This table compares Biopharmx Corp and Proteon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biopharmx Corp -22,005.88% -5,749.08% -240.31%
Proteon Therapeutics N/A -72.02% -64.41%

Risk and Volatility

Biopharmx Corp has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.

Insider & Institutional Ownership

47.1% of Proteon Therapeutics shares are owned by institutional investors. 36.3% of Proteon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


Proteon Therapeutics beats Biopharmx Corp on 7 of the 10 factors compared between the two stocks.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with's FREE daily email newsletter.